Gretchen Collum
Primary Care · Lexington, SCNPI 1568508141
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 248 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 13.2% — the pattern of someone who eats at a lot of different presentations.
Across 248 payments — averaging $18.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$603
- Novo Nordisk$494
- Lilly USA, LLC$451
- Pfizer$273
- Neurocrine Biosciences, Inc.$251
- Amgen$248
- plus $2K from 27 others
What the payments were for
- Food & beverage$4,568100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 31 | $603 |
| Novo Nordisk | 25 | $494 |
| Lilly USA, LLC | 30 | $451 |
| Pfizer | 17 | $273 |
| Neurocrine Biosciences, Inc. | 11 | $251 |
| Amgen | 14 | $248 |
| Novartis | 11 | $223 |
| Dexcom, Inc. | 8 | $203 |
| AbbVie | 11 | $195 |
| Sanofi-aventis U.S. LLC | 7 | $153 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $149 |
| Daiichi Sankyo Inc. | 7 | $147 |
| Abbott | 8 | $137 |
| Exact Sciences | 7 | $121 |
| Otsuka America Pharmaceutical, Inc. | 4 | $102 |
| Xeris Pharmaceuticals, Inc. | 4 | $78 |
| Boehringer Ingelheim | 5 | $73 |
| E.r. Squibb & Sons, L.L.C. | 5 | $69 |
| Esperion Therapeutics, Inc. | 4 | $65 |
| Sumitomo Pharma America, Inc. | 3 | $65 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $57 |
| Lundbeck LLC | 2 | $47 |
| Idorsia Pharmaceuticals US Inc | 3 | $43 |
| Merck | 2 | $42 |
| Astellas Pharma US Inc | 2 | $40 |
| Aimmune Therapeutics, Inc. | 2 | $35 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $34 |
| Johnson & Johnson | 2 | $32 |
| Phathom Pharmaceuticals, Inc. | 2 | $31 |
| Bayer | 2 | $30 |
| GSK | 2 | $30 |
| Cequr Corporation | 1 | $28 |
| Stryker | 1 | $19 |
How this compares
$4,568 in reported general payments places this provider in the 85th percentile of 115 primary care providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 12 | $14,320 |
| JardianceEmpagliflozin | 13 | $11,147 |
| OzempicSemaglutide | 13 | $11,124 |
| EliquisApixaban | 13 | $8,548 |
| PaxlovidNirmatrelvir/Ritonavir | 12 | $2,859 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 17 | $674 |
| Levothyroxine Sodium | 66 | $568 |
| Pantoprazole Sodium | 23 | $553 |
| Fluticasone Propionate | 25 | $434 |
| Montelukast Sodium | 19 | $433 |
| Atorvastatin Calcium | 26 | $425 |
| Metoprolol Succinate | 21 | $399 |
| Valsartan | 16 | $380 |
| Duloxetine Hcl | 14 | $347 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 38 | $335 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $451 | $14,32012 claims |
| PfizerEliquis, Paxlovid | $273 | $11,40725 claims |
| Boehringer IngelheimJardiance | $73 | $11,14713 claims |
| Novo NordiskOzempic | $494 | $11,12413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 115 primary care providers in South Carolina.
Other primary care in Lexington
- Sarah TomashefskiGreenville$23K
- Samantha VaughtNorth Myrtle Beach$15K
- Cynthia SmithSeneca$10K
- William ByrdSumter$10K
- Kathleen BoonePawleys Island$9K
- Amanda GroomeGreenville$9K
- Holly SurrencyAiken$8K
- Jessica BoldenAnderson$8K
- Caren ArnetteDillon$7K
- Heather MartinSeneca$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.